TTHI Share Price

Open 1.54 Change Price %
High 1.57 1 Day 0.00 0.00
Low 1.52 1 Week 0.00 0.00
Close 1.52 1 Month 0.00 0.00
Volume 12424 1 Year 0.78 105.41
52 Week High 1.70
52 Week Low 0.66
TTHI Important Levels
Resistance 2 1.57
Resistance 1 1.55
Pivot 1.54
Support 1 1.49
Support 2 1.47
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Transition Therapeutics, Inc. (NASDAQ: TTHI)

TTHI Technical Analysis 4
As on 30th Aug 2016 TTHI Share Price closed @ 1.52 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.37 & Strong Buy for SHORT-TERM with Stoploss of 1.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
TTHI Target for June
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TTHI Other Details
Segment EQ
Market Capital 60303716.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.transitiontherapeutics.com
TTHI Address
TTHI
101 College Street
Suite 220
Toronto, ON M5G 1L7
Canada
Phone: 416-260-7770
TTHI Latest News
Repare Therapeutics Raises US$68 Million Series A   Business Wire (press release)   - 22nd Jun 17
Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to ...   GlobeNewswire (press release)   - 22nd Jun 17
Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound from APC ...   PR Newswire (press release)   - 20th Jun 17
Clinical trial investigates Alzheimer's disease drug in people with Down syndrome   EurekAlert (press release)   - 01st Jun 17
BRIEF-Insys Therapeutics announces chief financial officer transition   Reuters   - 16th May 17
The Synergy From OPKO's Acquisition of Transition Therapeutics (OPK)   Investopedia   - 15th Sep 16
OPKO Health Completes Acquisition of Transition Therapeutics   Business Wire (press release)   - 31st Aug 16
Transition Therapeutics Announces Special Shareholder Meeting Voting Results ...   Canada NewsWire (press release)   - 26th Aug 16
OPKO Health (OPK) to Acquire Transition Therapeutics (TTHI) in $60M Deal   StreetInsider.com   - 30th Jun 16
Eli Lilly Can Save Transition Therapeutics Inc.   Seeking Alpha   - 30th Dec 15
Interactive Technical Analysis Chart Transition Therapeutics, Inc. ( TTHI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Transition Therapeutics, Inc.
TTHI Business Profile
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company�s s technologies in development are ELND005 (AZD-103) for the treatment of Alzheimer�s disease and bipolar disorder; TT-401/402 for the treatment of diabetes ,and TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, neuropathic pain, Alzheimer�s disease, traumatic brain injury and intracerebral haemorrhage. The Company has one wholly owned material subsidiary, Waratah Pharmaceuticals Inc. (Waratah), which is engaged in the development and commercialization of its ELND005 (AZD-103); the type II diabetes drug candidate TT-401; and TT-301 and TT-302.